PARSIPPANY, N.J. & TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's ...

for the treatment of postmenopausal women with osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy; to increase bone mass in men with ...

(RTTNews) - Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced Friday the approval of a generic version of Forteo in the United States. Forteo had ...

BEECH ISLAND, S.C.--(BUSINESS WIRE)--Ambio, Inc., an innovative biotech company developing novel peptide drugs, biosimilar, bioequivalent, and other complex generic drugs, announced today that a ...

Ambio announced that a generic version of Forteo (teriparatide injection) developed by Ambio and to be marketed and sold by Apotex has been approved by the Food and Drug Administration. Forteo ...

Please provide your email address to receive an email when new articles are posted on . Teriparatide administered through the RT-102 pill provided higher bioavailability than injection with no ...

Forteo (teriparatide) is a brand-name drug that doctors prescribe for some people with osteoporosis. It contains proteins that strengthen bones and stimulate new bone growth. A typical prescription is ...

Compared with teriparatide, abaloparatide treatment showed a greater reduction in fracture incidence among treatment-naïve postmenopausal individuals. Treatment with abaloparatide vs teriparatide is ...